Compare iShares MSCI France ETF (EWQ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Sanofi SA — how do they compare? iShares MSCI France ETF trades at $45.08, while Sanofi SA trades at $44.21 (market cap $103.94B). The key difference: Sanofi SA pays a 5.54% dividend while iShares MSCI France ETF pays none, and iShares MSCI France ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| EWQ | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $52.34 |
52-Week Low | $41.43 | $41.33 |
Market Cap | — | $103.94B |
Enterprise Value | — | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI France ETF (EWQ) is trading at $45.16, up 0.27% on the day, while exhibiting a bearish technical signal with 11 sell signals versus 6 buy signals. The fund faces headwinds from European Central Bank rate hikes and energy market volatility driven by Middle East tensions, though it offers exposure to French technology investments and a scheduled $1.09 dividend in June 2026.
Outlook remains cautious amid macroeconomic uncertainty, with investment opportunity tied to France's €13 billion tech sovereignty push and AI investments, balanced against risks from energy price shocks, potential job losses in key EU sectors, and geopolitical trade tensions that could impact European equities.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
